Literature DB >> 29601840

Protein Nanoparticles Promote Microparticle Formation in Intravenous Immunoglobulin Solutions During Freeze-Thawing and Agitation Stresses.

Neha N Pardeshi1, Chen Zhou1, Theodore W Randolph2, John F Carpenter3.   

Abstract

In this study, we investigated the potential roles of nanoparticles (<100 nm) and submicron (100-1000 nm) particles in the formation of microparticles (>1000 nm) in protein formulations under some pharmaceutically relevant stress conditions. Exposure of intravenous immunoglobulin solutions to the interface-associated stresses of freeze-thawing or agitation resulted in relatively large increases in microparticle concentrations, which depended directly on the levels of pre-existing nano- and submicron particles. Thus, agglomeration of nanoparticles and submicron particles appears to play a role in microparticle formation under these stresses. In contrast, increases in microparticle concentrations during quiescent incubation at elevated temperatures were independent of the initial nano- and submicron particle concentrations in solution.
Copyright © 2018 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  adsorption; degradation product(s); desorption; formulation; mAb(s); microparticle(s); nanoparticle(s); physical stability; protein aggregation; surfactant(s)

Mesh:

Substances:

Year:  2018        PMID: 29601840      PMCID: PMC6245654          DOI: 10.1016/j.xphs.2018.03.016

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  36 in total

1.  Subvisible particle counting provides a sensitive method of detecting and quantifying aggregation of monoclonal antibody caused by freeze-thawing: insights into the roles of particles in the protein aggregation pathway.

Authors:  James G Barnard; Satish Singh; Theodore W Randolph; John F Carpenter
Journal:  J Pharm Sci       Date:  2010-08-27       Impact factor: 3.534

Review 2.  Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis.

Authors:  Vincent Corvari; Linda O Narhi; Thomas M Spitznagel; Nataliya Afonina; Shawn Cao; Patricia Cash; Irene Cecchini; Michael R DeFelippis; Patrick Garidel; Andrea Herre; Atanas V Koulov; Tony Lubiniecki; Hanns-Christian Mahler; Paolo Mangiagalli; Douglas Nesta; Bernardo Perez-Ramirez; Alla Polozova; Mara Rossi; Roland Schmidt; Robert Simler; Satish Singh; Andrew Weiskopf; Klaus Wuchner
Journal:  Biologicals       Date:  2015-08-29       Impact factor: 1.856

Review 3.  Protein stability during freezing: separation of stresses and mechanisms of protein stabilization.

Authors:  Bakul S Bhatnagar; Robin H Bogner; Michael J Pikal
Journal:  Pharm Dev Technol       Date:  2007       Impact factor: 3.133

4.  Immunogenicity of aggregates of recombinant human growth hormone in mouse models.

Authors:  Amber Haynes Fradkin; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2009-09       Impact factor: 3.534

5.  IgG particle formation during filling pump operation: a case study of heterogeneous nucleation on stainless steel nanoparticles.

Authors:  Anil K Tyagi; Theodore W Randolph; Aichun Dong; Kevin M Maloney; Carl Hitscherich; John F Carpenter
Journal:  J Pharm Sci       Date:  2009-01       Impact factor: 3.534

6.  Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics.

Authors:  Maryam Ahmadi; Christine J Bryson; Edward A Cloake; Katie Welch; Vasco Filipe; Stefan Romeijn; Andrea Hawe; Wim Jiskoot; Matthew P Baker; Mark H Fogg
Journal:  Pharm Res       Date:  2015-04       Impact factor: 4.200

7.  Particle shedding from peristaltic pump tubing in biopharmaceutical drug product manufacturing.

Authors:  Verena Saller; Julia Matilainen; Ulla Grauschopf; Karoline Bechtold-Peters; Hanns-Christian Mahler; Wolfgang Friess
Journal:  J Pharm Sci       Date:  2015-01-20       Impact factor: 3.534

8.  Microparticles and Nanoparticles Delivered in Intravenous Saline and in an Intravenous Solution of a Therapeutic Antibody Product.

Authors:  Neha N Pardeshi; Wei Qi; Kevin Dahl; Liron Caplan; John F Carpenter
Journal:  J Pharm Sci       Date:  2016-11-07       Impact factor: 3.534

9.  Particles shed from syringe filters and their effects on agitation-induced protein aggregation.

Authors:  Lu Liu; Theodore W Randolph; John F Carpenter
Journal:  J Pharm Sci       Date:  2012-06-06       Impact factor: 3.534

10.  Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses.

Authors:  Marisa K Joubert; Martha Hokom; Catherine Eakin; Lei Zhou; Meghana Deshpande; Matthew P Baker; Theresa J Goletz; Bruce A Kerwin; Naren Chirmule; Linda O Narhi; Vibha Jawa
Journal:  J Biol Chem       Date:  2012-05-14       Impact factor: 5.157

View more
  1 in total

1.  Subvisible Particles in IVIg Formulations Activate Complement in Human Serum.

Authors:  Carly F Chisholm; William Behnke; Yekaterina Pokhilchuk; Ashley A Frazer-Abel; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2019-10-28       Impact factor: 3.534

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.